188 related articles for article (PubMed ID: 25338609)
1. [Research progress of epigenetic drug decitabine in AML].
Zhang R; Li HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1467-71. PubMed ID: 25338609
[TBL] [Abstract][Full Text] [Related]
2. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
3. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
4. A single nucleotide polymorphism chip-based method for combined genetic and epigenetic profiling: validation in decitabine therapy and tumor/normal comparisons.
Yuan E; Haghighi F; White S; Costa R; McMinn J; Chun K; Minden M; Tycko B
Cancer Res; 2006 Apr; 66(7):3443-51. PubMed ID: 16585166
[TBL] [Abstract][Full Text] [Related]
5. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
[TBL] [Abstract][Full Text] [Related]
6. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.
Claus R; Pfeifer D; Almstedt M; Zucknick M; Hackanson B; Plass C; Lübbert M
Leuk Res; 2013 Feb; 37(2):190-6. PubMed ID: 23158571
[TBL] [Abstract][Full Text] [Related]
7. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Estey EH
Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
[TBL] [Abstract][Full Text] [Related]
8. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
9. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Gore L; Triche TJ; Farrar JE; Wai D; Legendre C; Gooden GC; Liang WS; Carpten J; Lee D; Alvaro F; Macy ME; Arndt C; Barnette P; Cooper T; Martin L; Narendran A; Pollard J; Meshinchi S; Boklan J; Arceci RJ; Salhia B
Clin Epigenetics; 2017; 9():108. PubMed ID: 29034009
[TBL] [Abstract][Full Text] [Related]
10. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.
Hiller JK; Schmoor C; Gaidzik VI; Schmidt-Salzmann C; Yalcin A; Abdelkarim M; Blagitko-Dorfs N; Döhner K; Bullinger L; Duyster J; Lübbert M; Hackanson B
Ann Hematol; 2017 Apr; 96(4):559-565. PubMed ID: 28058491
[TBL] [Abstract][Full Text] [Related]
12. Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes.
Bohl SR; Dolnik A; Jensen T; Lang KM; Hackanson B; Gaidzik VI; Paschka P; Knudsen S; Döhner K; Döhner H; Claus R; Lübbert M; Bullinger L
Leuk Lymphoma; 2017 Sep; 58(9):1-4. PubMed ID: 28278722
[No Abstract] [Full Text] [Related]
13. The role of hypomethylating agents in the treatment of elderly patients with AML.
Al-Ali HK; Jaekel N; Niederwieser D
J Geriatr Oncol; 2014 Jan; 5(1):89-105. PubMed ID: 24484723
[TBL] [Abstract][Full Text] [Related]
14. Clinical development of demethylating agents in hematology.
Navada SC; Steinmann J; Lübbert M; Silverman LR
J Clin Invest; 2014 Jan; 124(1):40-6. PubMed ID: 24382388
[TBL] [Abstract][Full Text] [Related]
15. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
16. Hypomethylating Agents as a Therapy for AML.
Gardin C; Dombret H
Curr Hematol Malig Rep; 2017 Feb; 12(1):1-10. PubMed ID: 28286907
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic therapy with decitabine for myelodysplasia and leukemia.
Wijermans P; Lübert M
Future Oncol; 2005 Oct; 1(5):585-91. PubMed ID: 16556035
[TBL] [Abstract][Full Text] [Related]
18. Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.
Yun H; Damm F; Yap D; Schwarzer A; Chaturvedi A; Jyotsana N; Lübbert M; Bullinger L; Döhner K; Geffers R; Aparicio S; Humphries RK; Ganser A; Heuser M
Haematologica; 2014 Sep; 99(9):1456-64. PubMed ID: 24895338
[TBL] [Abstract][Full Text] [Related]
19. MLL5 expression as a biomarker for DNA hypermethylation and sensitivity to epigenetic therapy.
Milne TA
Haematologica; 2014 Sep; 99(9):1405-7. PubMed ID: 25176980
[No Abstract] [Full Text] [Related]
20. Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia.
Zhou S; Liu P; Zhang H
Mol Med Rep; 2017 Jul; 16(1):281-287. PubMed ID: 28498449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
